anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Prasugrel
Trial phase: Phase 4
ATC code: B01AC22
SMILES: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: Prasugrel 60mg loading dose as crushed tablets
Eligibility criteria:
Inclusion criteria:

Patients with ST-elevation myocardial infarction undergoing primary PCI
Age between 18 and 75 years old

Exclusion criteria:

Age >75 years
Weight <60 Kg
On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in past 7 days
Known allergies to aspirin or prasugrel
Considered at high risk for bleeding
History of ischemic or hemorrhagic stroke or transient ischemic attack
On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban, apixaban)
Treatment with IIb/IIIa glycoprotein inhibitors
Fibrinolytics within 24 hours
Known blood dyscrasia or bleeding diathesis
Known platelet count <80x106/mL
Known hemoglobin <10 g/dL
Active bleeding
Hemodynamic instability
Known creatinine clearance <30 mL/minute
Known severe hepatic dysfunction

Pregnant females*

Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.
Intervention: Prasugrel
Trial phase: Phase 4
ATC code: B01AC22
SMILES: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: Prasugrel 60 mg loading dose whole tablets
Eligibility criteria:
Inclusion criteria:

Patients with ST-elevation myocardial infarction undergoing primary PCI
Age between 18 and 75 years old

Exclusion criteria:

Age >75 years
Weight <60 Kg
On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in past 7 days
Known allergies to aspirin or prasugrel
Considered at high risk for bleeding
History of ischemic or hemorrhagic stroke or transient ischemic attack
On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban, apixaban)
Treatment with IIb/IIIa glycoprotein inhibitors
Fibrinolytics within 24 hours
Known blood dyscrasia or bleeding diathesis
Known platelet count <80x106/mL
Known hemoglobin <10 g/dL
Active bleeding
Hemodynamic instability
Known creatinine clearance <30 mL/minute
Known severe hepatic dysfunction

Pregnant females*

Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.
Intervention: Acetylcysteine
Trial phase: Phase 2
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Subjects will be provided 6000 mg/day of N-acetylcysteine (capsule) to be divided into 2 equal daily doses and taken orally for approximately 28 days

N-acetylcysteine capsule: N-acetylcysteine capsule
Eligibility criteria:
Inclusion Criteria:

All participants must be 18 years or older
All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent
Individuals with medically stable Parkinson's disease (in the opinion of the investigator)
All participants must not have taken antioxidants NAC, glutathione, coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study
Absence of dementia in all subjects

Exclusion Criteria:

Inability to undergo MRI scanning without sedation and other MRI counterindications, such as metal in the body (see section 7.3)
Medically unstable conditions as determined by the investigators
Pregnant or lactating or those women of child-bearing age that are not using acceptable forms of contraception
Diagnosis of asthma that is presently being treated with any medication, or past history of asthma/bronchospasm resulting in an emergency room visit, hospitalization or treatment
Unable to adhere to study protocol for whatever reason
Intervention: NIACINAMIDE
Trial phase: Phase 1
ATC code: A11HA01
SMILES: NC(=O)c1cccnc1
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Nicotinamide 500 mg by mouth each morning until delivery or 14 days, whichever occurs first.
Eligibility criteria:
Inclusion Criteria:

Maternal age 18-45 years
Informed written consent

Preeclampsia or new onset hypertension between 24-32 completed weeks' gestation

Hypertensive complications of pregnancy defined as new onset systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg on two occasions 6 hours apart; OR > 300 mg proteinuria on 24 hour urine collection OR urine P/C ratio >0.3;
Dating criteria based on menstrual dating confirmed by first or second trimester ultrasound OR second trimester ultrasound if menstrual dating unavailable;
Deemed clinically stable by primary clinician and candidate for expectant management (delayed delivery);
Maternal liver function tests < 3x ULN
Maternal platelet count > 100,000 mm3
Fetal well-being established by estimated fetal weight > 5th %tile; normal amniotic fluid volume (MVP > 2 cm); normal Umbilical Artery Dopplers; AND reactive NST(non-stress test) or BPP (biophysical profile) > 6
Plan for expectant management until delivery
Delivery not anticipated within first 48 hours

Exclusion Criteria:

Preeclampsia < 24 or > 33 weeks' gestation;
Suspected fetal structural or chromosomal abnormality;
Pre-existing renal disease (creatinine > 1.5 mg/dL)
Pre-existing vascular disease (systemic lupus; cardiac disease;)
Plan for delivery within 48 hours
Any pre-existing medical condition that would increase risk for liver toxicity (e.g. hepatitis B or C; HIV)
Evidence of cerebral dysfunction (seizures; cerebral edema on CT/MRI; headache unresolved with oral analgesics)
Pulmonary edema
HELLP (hemolysis, elevated liver enzymes, low platelets syndrome)
Evidence of liver dysfunction (LFTs > 3x ULN)
Thrombocytopenia (platelets < 100,000 mm3)
Evidence of fetal compromise: EFW(estimated fetal weight) < 5th percentile; BPP < 6; absent or reverse diastolic UA blood flow; oligohydramnios (MVP < 2 cm)
Placental abruption defined as unexplained vaginal bleeding
Preterm labor defined as regular contractions and cervical change
Any condition deemed by the investigator to be a risk to mother or fetus in completion of the study
Any condition deemed by the investigator to require delivery within 48 hours
Intervention: NIACINAMIDE
Trial phase: Phase 1
ATC code: A11HA01
SMILES: NC(=O)c1cccnc1
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Nicotinamide 1000 mg by mouth each morning until delivery or 14 days, whichever occurs first.
Eligibility criteria:
Inclusion Criteria:

Maternal age 18-45 years
Informed written consent

Preeclampsia or new onset hypertension between 24-32 completed weeks' gestation

Hypertensive complications of pregnancy defined as new onset systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg on two occasions 6 hours apart; OR > 300 mg proteinuria on 24 hour urine collection OR urine P/C ratio >0.3;
Dating criteria based on menstrual dating confirmed by first or second trimester ultrasound OR second trimester ultrasound if menstrual dating unavailable;
Deemed clinically stable by primary clinician and candidate for expectant management (delayed delivery);
Maternal liver function tests < 3x ULN
Maternal platelet count > 100,000 mm3
Fetal well-being established by estimated fetal weight > 5th %tile; normal amniotic fluid volume (MVP > 2 cm); normal Umbilical Artery Dopplers; AND reactive NST(non-stress test) or BPP (biophysical profile) > 6
Plan for expectant management until delivery
Delivery not anticipated within first 48 hours

Exclusion Criteria:

Preeclampsia < 24 or > 33 weeks' gestation;
Suspected fetal structural or chromosomal abnormality;
Pre-existing renal disease (creatinine > 1.5 mg/dL)
Pre-existing vascular disease (systemic lupus; cardiac disease;)
Plan for delivery within 48 hours
Any pre-existing medical condition that would increase risk for liver toxicity (e.g. hepatitis B or C; HIV)
Evidence of cerebral dysfunction (seizures; cerebral edema on CT/MRI; headache unresolved with oral analgesics)
Pulmonary edema
HELLP (hemolysis, elevated liver enzymes, low platelets syndrome)
Evidence of liver dysfunction (LFTs > 3x ULN)
Thrombocytopenia (platelets < 100,000 mm3)
Evidence of fetal compromise: EFW(estimated fetal weight) < 5th percentile; BPP < 6; absent or reverse diastolic UA blood flow; oligohydramnios (MVP < 2 cm)
Placental abruption defined as unexplained vaginal bleeding
Preterm labor defined as regular contractions and cervical change
Any condition deemed by the investigator to be a risk to mother or fetus in completion of the study
Any condition deemed by the investigator to require delivery within 48 hours
Intervention: Premarin
Trial phase: Phase 4
ATC code: G03CA57
SMILES: CC12CCC3c4ccc(OS(=O)(=O)[O-])cc4CCC3C1CCC2=O.[Na+]
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.

Premarin vaginal estrogen cream
Eligibility criteria:
Inclusion Criteria:

Post-menopausal women
Asymptomatic microscopic hematuria (three or more red blood cells per high powered field on a single urine microscopy) in the absence of urinary tract infection.

Exclusion Criteria:

Known urologic disease
Presence of gross hematuria
Presence of indwelling urologic foreign body (foley catheter, ureteral stent)
Inability to obtain intravenous contrast CT scan (elevated creatinine, severe contrast allergy)
History of pelvic irradiation or malignancy

Not a candidate for vaginal estrogen

Allergy to vaginal estrogen
Current or prior diagnosis of breast or endometrial cancer
History of deep vein thrombosis/pulmonary embolus
Hypercoagulable state
Intervention: Carbamazepine
Trial phase: Phase 4
ATC code: N03AF01
SMILES: NC(=O)N1c2ccccc2C=Cc2ccccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Administered in gradual doses from 100 mg twice a day increasing to no more than 400 mg twice a day if symptoms do not reduce. After 2 weeks of steady dose drug will be tapered down every 3 days.

Carbamazepine: Day 1: Take 200 mg twice a day. Day 2: Take 200 mg twice a day.

Day 3: Take 200 mg twice a day. Day 4: Take 200 mg twice a day. Day 5: Take 400 mg twice a day. Day 6: Take 400 mg twice a day. Day 7: Take 400 mg twice a day. Day 8: Take 400 mg twice a day. Day 9: Take 600 mg twice a day. Day 10: Take 600 mg twice a day. Day 11: Take 600 mg twice a day. Day 12: Take 600 mg twice a day. Day 13: Take 800 mg capsules twice a day. Day 14: Take 800 mg twice a day. Day 15: 800 mg twice a day. Day 16: Take 800 mg twice a day.

Taper Down (After Visit 4 and 7) If maximal dose of 800 mg/day has been achieved, tapering down will take 9 days Taper down for 600 mg/day will take 6 days, and for 400 mg/day will take 3 days.
Eligibility criteria:
Inclusion Criteria:

diagnosis/symptoms of EM
specific NaV1.7 sodium channel mutations (including S241T)

Exclusion Criteria:

patients with no identified NaV1.7 mutation
Intervention: Pregabalin
Trial phase: Phase 2
ATC code: N02BF02 | N03AX16
SMILES: CC(C)C[C@H](CN)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 46
Group description: Participants received pregabalin, oral capsule, 150 mg/day, then 300 mg/day from Day 8, for 4 weeks.
Eligibility criteria:
Inclusion Criteria:

Men and women aged 18 years to 80 years.
Diagnosis of Type 2 diabetes mellitlus (T2DM) with current glycosylated hemoglobin A1c (HbA1c) levels of ≤ 11% at Screening and on a stable antidiabetic medication regimen for at least 30 days prior to randomization.
Presence of ongoing pain due to DPN for at least 6 months.
Willing to discontinue protocol-specified prohibited pain medications for DPN throughout the duration of the study.

Exclusion Criteria:

Painful neuropathies or painful conditions other than DPN that may confound evaluation of pain due to DPN during the study.
Subjects who have failed previously on pregabalin (at the recommended label dose and for adequate duration) due to lack of efficacy.
Subjects with any clinically significant medical or psychiatric conditions or clinically significant laboratory test abnormalities.
Pregnant women, lactating mothers, men with partners currently pregnant, women suspected of being pregnant, and women who wish to be pregnant during the course of the clinical study.
Intervention: PF-04457845
Trial phase: Phase 2
SMILES: O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 8
Group description: PF-04457845 4 milligrams (mg) was orally administered once daily in the morning on Days 1 to 7.
Eligibility criteria:
Inclusion Criteria:

Men and women 18-60 years of age with a primary psychiatric diagnosis of Post Traumatic Stress Disorder

Exclusion Criteria:

Other psychiatric illness requiring current treatment with medication.
Intervention: Growth hormone
Trial phase: Phase 2
SMILES: CC(C)CC1NC(=O)C(CCC(=O)O)NC(=O)C2CSSCC3NC(=O)C(C)NC(=O)C4CCCN4C(=O)C(CC(N)=O)NC(=O)C(CSSCC(NC(=O)C(Cc4ccc(O)cc4)NC(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(N)CC(N)=O)C(=O)N2)NC(=O)C(CSSC(C(=O)NC(Cc2ccc(O)cc2)C(=O)O)NC(=O)CNC(=O)C(C(C)O)NC3=O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Growth Hormone (GH) is Genotropin, provided by Pfizer Inc. It is a self-administered sub-cutaneous daily injection using an injection pen device. It was administered for 6 months. The dose was titrated based on IGF-1 hormone levels with the goal of maintaining an IGF-1 level in the upper-quartile of the normal range.
Eligibility criteria:
Inclusion Criteria:

Ages 18 - 65 yr
NAFLD defined as demonstration of hepatic steatosis by imaging or biopsy in absence of significant alcohol consumption and other causes of hepatic steatosis. If liver imaging or biopsy has not been performed clinically, liver ultrasound will be performed as part of the screening visit.

Exclusion Criteria:

Serum creatinine > 2 times the upper limit of normal
History of cancer, except for non-melanoma skin cancers
Active carpel tunnel syndrome
Diabetes mellitus, defined as a hemoglobin A1C >6.5 or use of any medications prescribed to treat hyperglycemia. The exception is that the use of metformin is acceptable in patients whose HbA1c has been =<6.0 on two visits and whose weight has remained stable for six months.
Contraindications to magnetic resonance imaging (MRI).
Pregnancy or desire to become pregnant. Participants of reproductive age must agree to use contraception.
Breastfeeding
Aspartate and aminotransferase levels >10x upper limit of normal
Intervention: Adomeglivant
Trial phase: Phase 1
SMILES: Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 16
Group description: Single oral dose of 20 mg LY2409021.
Eligibility criteria:
Inclusion Criteria:

Healthy males or females as determined by medical history
Satisfactory clinical laboratory and physical examination tests
Have a body mass index (BMI) of 18 to 32.0 kilograms per meter squared (kg/m^2)

Exclusion Criteria:

- Abnormal electrocardiograms (ECGs)
Intervention: Alvimopan
Trial phase: Not Applicable
ATC code: A06AH02
SMILES: C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 13
Group description: Alvimopan 12mg once orally two hours prior to surgery and then 2 mg orally twice a day until post-operative day (POD) seven.

Alvimopan
Eligibility criteria:
Inclusion Criteria:

adult patients undergoing elective PSF of at least 5 levels and/or fixation to pelvis

Exclusion Criteria:

pregnant women
ischemic heart disease
chronic liver or renal disease
prior bowel resection
presence of colostomy or ileostomy
gastroparesis
complete bowel obstruction
inflammatory bowel disease (ulcerative colitis or Crohn's disease).
Intervention: Mupirocin
Trial phase: Phase 4
ATC code: D06AX09 | R01AX06
SMILES: C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 68
Group description: topical antibiotic

Mupirocin
Eligibility criteria:
Inclusion Criteria:

Chronic Rhinosinusitis
Undergoing endoscopic sinus surgery

Exclusion Criteria:

Age under 18
Documented adverse reaction to mupirocin
Intervention: Magnesium
Trial phase: Phase 2 | Phase 3
SMILES: [MgH2]
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 60
Group description: Intravenous magnesium. After IV placed intraoperatively, a bolus dose of magnesium 30 mg/kg is given over 15 minutes, followed by a continuous infusion of magnesium at 10 mg/kg/hr until the completion of the procedure.

Magnesium
Eligibility criteria:
Inclusion Criteria:

Patients aged 4-10 years old undergoing tonsillectomy by a single surgeon and under the care of that participating surgeon
American Society of Anesthesiology (ASA) patient classification of I-III

Exclusion Criteria:

Physical or developmental delay
Psychiatric illness
Current use of sedative or anticonvulsant medication
Pre-existing renal disease
Pre-existing cardiovascular disease
Regular use of analgesic medication
Having other procedures in addition to tonsillectomy (however, patients undergoing adenoidectomy with their tonsillectomy will be included in the study)
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2 | Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 60
Group description: Intravenous normal saline will be given as placebo. An equal amount of volume normal saline will be given intravenously as the control group.

Normal saline
Eligibility criteria:
Inclusion Criteria:

Patients aged 4-10 years old undergoing tonsillectomy by a single surgeon and under the care of that participating surgeon
American Society of Anesthesiology (ASA) patient classification of I-III

Exclusion Criteria:

Physical or developmental delay
Psychiatric illness
Current use of sedative or anticonvulsant medication
Pre-existing renal disease
Pre-existing cardiovascular disease
Regular use of analgesic medication
Having other procedures in addition to tonsillectomy (however, patients undergoing adenoidectomy with their tonsillectomy will be included in the study)
Intervention: Cetaphil
Trial phase: Not Applicable
SMILES: CC(O)CO.CCCCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCOS(=O)(=O)[O-].CCCCOC(=O)c1ccc(O)cc1.CCCOC(=O)c1ccc(O)cc1.COC(=O)c1ccc(O)cc1.[Na+]
Sex: Female
Age groups: Child
Healthy volunteers: No
Participants at risk: 21
Group description: Apply a pea-sized amount to the labial adhesion with lateral traction twice daily

Cetaphil: Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Eligibility criteria:
Inclusion Criteria:

Prepubertal girls ages 3 months to 12 years with labial adhesions

Exclusion Criteria:

Presence of underlying dermatologic conditions such as lichen sclerosis, severe atopic dermatitis, psoriasis or vitiligo
Presence of systemic conditions that can have vulvar manifestations such as Crohn's disease and Behçet disease
Presence of disorders requiring immunosuppressant treatment
Previous surgical separation of labial adhesions
Intervention: Estradiol
Trial phase: Not Applicable
ATC code: G02BB01 | G03AA14 | G03AA17 | G03AB08 | G03CA03 | G03CA53 | G03EA01 | G03EA02 | G03EA03 | G03FA01 | G03FA02 | G03FA03 | G03FA04 | G03FA05 | G03FA06 | G03FA07 | G03FA08 | G03FA09 | G03FA10 | G03FA11 | G03FA12 | G03FA13 | G03FA14 | G03FA15 | G03FA16 | G03FA17 | G03FB01 | G03FB02 | G03FB03 | G03FB04 | G03FB05 | G03FB06 | G03FB07 | G03FB08 | G03FB09 | G03FB10 | G03FB11 | G03FB12 | G03HB01 | H01CC53 | H01CC54
SMILES: [H][C@@]12CCc3cc(O)ccc3[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H]
Sex: Female
Age groups: Child
Healthy volunteers: No
Participants at risk: 22
Group description: Apply a pea-sized amount to the labial adhesion with lateral traction twice daily

Estradiol cream 0.01%: Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Eligibility criteria:
Inclusion Criteria:

Prepubertal girls ages 3 months to 12 years with labial adhesions

Exclusion Criteria:

Presence of underlying dermatologic conditions such as lichen sclerosis, severe atopic dermatitis, psoriasis or vitiligo
Presence of systemic conditions that can have vulvar manifestations such as Crohn's disease and Behçet disease
Presence of disorders requiring immunosuppressant treatment
Previous surgical separation of labial adhesions
Intervention: PF-03715455
Trial phase: Phase 2
SMILES: CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Participants received PF-03715455 680 micrograms (mcg) twice a day for 12 weeks via oral inhalation using the Miat monodose inhaler.
Eligibility criteria:
Inclusion Criteria:

Subjects with a physician documented history or diagnosis of persistent asthma (according to GINA, 2014 definition of asthma),
Pre bronchodilator FEV1 of greater than or equal to 50 and less that 80% of predicted.
Subjects defined as GINA Step 4 on a stable dose of either fluticasone/salmeterol combination therapy, or budesonide/formoterol combination therapy or mometasone/formoterol combination therapy.
Subjects who are defined as uncontrolled as evidenced by; Juniper Asthma Control Questionnaire (5 item version, ACQ) score greater than or equal to 1.5 and less than or equal to 3.0)

Exclusion Criteria:

Subjects diagnosed with chronic pulmonary disease (COPD) and/or other chronic pulmonary diseases (eg, Occupational asthma, pulmonary fibrosis, bronchiectasis, Allergic bronchopulmonary aspergillosis (ABPA), pneumoconiosis, sarcoidosis, tuberculosis).
Subjects who are current smokers.
Intervention: Bupivacaine
Trial phase: Not Applicable
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Liposomal bupivacaine (diluted to 60mL): 20mL into the posterior pocket, 20mL into the lateral, and 20mL into the medial, including all deep and superficial tissues of these areas.

Liposomal bupivacaine
Eligibility criteria:
Inclusion Criteria:

At least 18 years of age
Scheduled to undergo total knee arthroplasty (TKA) performed by the principal investigator

Exclusion Criteria:

Age <18 years
Pregnant or breastfeeding
Non-English-speaking
Unable to give informed consent
Patients admitted from or discharged to a medical facility (due to likelihood of limited mobility and/or required minimum lengths of stay, confounding primary outcome), including other hospitals, skilled nursing facilities, long-term acute care hospitals, etc.
Patients unable to complete a device-assisted 140 foot walk at baseline
Patients with contraindication(s) to any bupivacaine or ropivacaine formulation, to nerve blocks or any of the local agents used (IV morphine, ketorolac, or methylprednisolone).
Patients on a long-acting maintenance opioid prior to admission for surgery (e.g., methadone, oxycontin)
Patients undergoing simultaneous bilateral TKAs, as this would increase the dose of Exparel per patient (we are limited to one dose per patient)